We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

94 hedge funds and large institutions have $357M invested in KalVista Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more capital invested

Capital invested by funds: $237M → $357M (+$120M)

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

5.38% more ownership

Funds ownership: 98.85% → 104.23% (+5.4%)

3% more funds holding

Funds holding: 91 → 94 (+3)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

6% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 31

Holders
94
Holders Change
+3
Holders Change %
+3.3%
% of All Funds
1.62%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
15
Increased
29
Reduced
31
Closed
12
Calls
$9.88M
Puts
–
Net Calls
+$9.88M
Net Calls Change
+$3.88M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$12M
2
DCM
Driehaus Capital Management
Illinois
+$7.4M
3
Millennium Management
Millennium Management
New York
+$5.28M
4
IBT
International Biotechnology Trust
United Kingdom
+$4.37M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$4.28M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$4.67M
2
PM
Prosight Management
Texas
-$4.06M
3
SCM
Suvretta Capital Management
New York
-$3.09M
4
LCM
Laurion Capital Management
New York
-$1.72M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
DAFNA Capital Management
California
$3.71M -$145K -10,350 -4%
Northern Trust
27
Northern Trust
Illinois
$3.55M +$6.68K +478 +0.2%
Walleye Capital
28
Walleye Capital
New York
$2.16M -$775K -55,471 -27%
Citadel Advisors
29
Citadel Advisors
Florida
$2.02M -$472K -33,759 -19%
JP Morgan Chase
30
JP Morgan Chase
New York
$1.98M -$107K -7,657 -5%
Renaissance Technologies
31
Renaissance Technologies
New York
$1.8M -$1.47M -105,270 -46%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$1.66M -$126K -9,000 -7%
AAA
33
Affinity Asset Advisors
New York
$1.4M +$1.35M +96,318 New
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.39M +$415K +29,704 +45%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.2M +$134K +9,597 +13%
N
36
Nuveen
North Carolina
$1.16M +$7.48K +535 +0.7%
NFGH
37
Nan Fung Group Holdings
Hong Kong
$1.14M – – –
Charles Schwab
38
Charles Schwab
California
$916K +$3.03K +217 +0.3%
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
$859K -$212K -15,171 -20%
Point72 Asset Management
40
Point72 Asset Management
Connecticut
$839K +$808K +57,800 New
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
$642K -$150K -10,707 -19%
BC
42
Birchview Capital
Vermont
$580K – – –
AC
43
Apogem Capital
New York
$548K -$337K -24,103 -39%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$544K +$39.8K +2,844 +8%
Morgan Stanley
45
Morgan Stanley
New York
$448K -$397K -28,437 -48%
T. Rowe Price Associates
46
T. Rowe Price Associates
Maryland
$391K +$83.1K +5,947 +28%
EW
47
Evoke Wealth
California
$371K – – –
GCP
48
GSA Capital Partners
United Kingdom
$250K -$299K -21,414 -55%
AllianceBernstein
49
AllianceBernstein
Tennessee
$248K +$27.5K +1,964 +13%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$244K +$895 +64 +0.4%
1
2
3 4 5

KALV Hedge Fund Activity: Q3 2022 in Review

94 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2022, worth a combined $357M — up 50% from $237M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KALV positions and 12 closed out — a net gain of 3 holders — while 29 added to existing stakes and 31 trimmed.

The largest buyer was OrbiMed, adding an estimated $12M. The largest seller was Woodline Partners, cutting an estimated $4.67M.

  • 94 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2022, up from 91 in Q2 2022.
  • Funds reported $357M of KalVista Pharmaceuticals stock for Q3 2022, up 50% quarter-over-quarter.
  • 15 funds opened new KalVista Pharmaceuticals positions in Q3 2022 and 12 closed out, a net change of +3 holders.
  • The largest KalVista Pharmaceuticals buyer in Q3 2022 was OrbiMed, an estimated $12M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2022 was Woodline Partners, an estimated $4.67M sold.

Based on aggregated 13F filings for Q3 2022.